HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House, Senate Differ In Treating FDA China Syndrome

This article was originally published in The Tan Sheet

Executive Summary

Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.

You may also be interested in...



In Brief

Sen. Hatch on path to re-election; Senate passes FDA Safety and Innovation Act; DSM petitions FDA for folic acid fortification of masa flour; Nutrition 21 returns under new management; ZO Skin Health defends trademarks; more news In Brief.

Senate Appropriators Call For Botanical Identity Testing Guidance

A Senate FDA appropriation report says the guidance would enhance the agency’s ability to inspect and assess industry practices for manufacturing botanical dietary supplements. A National Center for Natural Products Research official says most botanical ingredients lack standard identity tests.

Sanofi-Aventis offer

Sanofi-Synthelabo extends its offer for Aventis U.S. shareholders to exchange their shares for Sanofi stock until June 30, Sanofi announces. The original deadline of May 28 was extended pending a decision by the French stock market regulator Autrite des Marches Financiers to set an expiration date. Sanofi has articulated a desire to close the $65 bil. merger in the second quarter. The firm also is awaiting final clearance from the Federal Trade Commission. Aventis accepted Sanofi's offer April 25 (1"The Tan Sheet" May 3, 2004, p. 8)...

Topics

UsernamePublicRestriction

Register

RS124910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel